GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug Galapagos gets cold feet over plans to split up company Atara lays off more staff this year despite FDA lifting clinical hold Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment' Appeals court reignites CRISPR discovery row, raising questions about gene editing biotech patents Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset J&J, Eli Lilly join $85M financing for newly unveiled gene editing biotech Stylus Former Inhibikase leader launches new biotech for midstage Parkinson’s asset | 